Oral Chinese Patent Medicine Combined With Oxaliplatin-Based Chemotherapy Regimen for the Treatment of Colorectal Cancer: A Network Meta-Analysis

Objective: To access the comparative effectiveness and safety of different oral Chinese patent medicine (OCPM) versus oxaliplatin-based chemotherapy regimen (C) alone for colorectal cancer (CRC) through network meta-analysis (NMA). Methods: Several electronic databases were searched for randomized c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mo Tang PhD Student, Bin He Doctor, Jiawei Zhai Master, Lei Wang PhD Student
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/04521a5b15b745b0b8b45078ebadc178
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:04521a5b15b745b0b8b45078ebadc178
record_format	dspace
spelling	oai:doaj.org-article:04521a5b15b745b0b8b45078ebadc1782021-12-02T01:03:46ZOral Chinese Patent Medicine Combined With Oxaliplatin-Based Chemotherapy Regimen for the Treatment of Colorectal Cancer: A Network Meta-Analysis1552-695X10.1177/15347354211058169https://doaj.org/article/04521a5b15b745b0b8b45078ebadc1782021-11-01T00:00:00Zhttps://doi.org/10.1177/15347354211058169https://doaj.org/toc/1552-695XObjective: To access the comparative effectiveness and safety of different oral Chinese patent medicine (OCPM) versus oxaliplatin-based chemotherapy regimen (C) alone for colorectal cancer (CRC) through network meta-analysis (NMA). Methods: Several electronic databases were searched for randomized controlled trials (RCTs) concentrated on the use of OCPM to treat CRC with C from the inception of the databases to January 10, 2021. We performed frequentist NMA and indirect comparison to compare study outcomes from the included RCTs. The risk of bias of each study was assessed using the Cochrane risk of bias tool. Confidence in evidence was assessed using Confidence in Network Meta-Analysis (CINeMA). Results: A total of 31 RCTs with 1985 participants comparing 10 OCPM, namely, Antike (ATK), Shenyi (SY), Huachansu (HCS), Boerning (BEN), Xiaoaiping (XAP), Jinlong (JL), Compound matrine (CC), Pingxiao (PX), Xihuang pill (XHW), Kangaiping (KAP) were identified. The methodological quality of included RCTs was not very high. The results of the NMA showed that the comparisons were all indirect. Among diverse OCPM, ATK + C had the highest objective response rate (ORR) with a P -score of .63 with risk ratio (RR) of 1.37 (95% CI 1.12-1.66); with a RR of 1.96 (1.26-3.05), SY + C had the highest performance status with a P -score of .73; KAP + C had the lowest nausea and vomiting with a P -score of .91 and with a RR of 0.29 (0.10-0.79); and JL + C had lowest leukopenia with a P -score of .95 with a RR of 0.47 (0.31-0.72). The results of pairwise comparison suggested no difference in outcomes among 10 kinds of OCPM + C. The comparison-adjusted funnel plots suggested that there might not be small-study effects for outcomes. According to the CINeMa approach, the confidence rating of this NMA ranged from “very low” to “low” for various comparisons. Conclusion: Based on the NMA, ATK + C, SY + C, KAP + C and JL + C were associated with more preferable and options for CRC patients when referring to ORR, performance status, nausea and vomiting, and leukopenia, respectively. However, owing to the limitations of this research, the above conclusions require further verification by more high-quality RCTs. PROSPERO registration: CRD42020160658.Mo Tang PhD StudentBin He DoctorJiawei Zhai MasterLei Wang PhD StudentSAGE PublishingarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENIntegrative Cancer Therapies, Vol 20 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Mo Tang PhD Student Bin He Doctor Jiawei Zhai Master Lei Wang PhD Student Oral Chinese Patent Medicine Combined With Oxaliplatin-Based Chemotherapy Regimen for the Treatment of Colorectal Cancer: A Network Meta-Analysis
description	Objective: To access the comparative effectiveness and safety of different oral Chinese patent medicine (OCPM) versus oxaliplatin-based chemotherapy regimen (C) alone for colorectal cancer (CRC) through network meta-analysis (NMA). Methods: Several electronic databases were searched for randomized controlled trials (RCTs) concentrated on the use of OCPM to treat CRC with C from the inception of the databases to January 10, 2021. We performed frequentist NMA and indirect comparison to compare study outcomes from the included RCTs. The risk of bias of each study was assessed using the Cochrane risk of bias tool. Confidence in evidence was assessed using Confidence in Network Meta-Analysis (CINeMA). Results: A total of 31 RCTs with 1985 participants comparing 10 OCPM, namely, Antike (ATK), Shenyi (SY), Huachansu (HCS), Boerning (BEN), Xiaoaiping (XAP), Jinlong (JL), Compound matrine (CC), Pingxiao (PX), Xihuang pill (XHW), Kangaiping (KAP) were identified. The methodological quality of included RCTs was not very high. The results of the NMA showed that the comparisons were all indirect. Among diverse OCPM, ATK + C had the highest objective response rate (ORR) with a P -score of .63 with risk ratio (RR) of 1.37 (95% CI 1.12-1.66); with a RR of 1.96 (1.26-3.05), SY + C had the highest performance status with a P -score of .73; KAP + C had the lowest nausea and vomiting with a P -score of .91 and with a RR of 0.29 (0.10-0.79); and JL + C had lowest leukopenia with a P -score of .95 with a RR of 0.47 (0.31-0.72). The results of pairwise comparison suggested no difference in outcomes among 10 kinds of OCPM + C. The comparison-adjusted funnel plots suggested that there might not be small-study effects for outcomes. According to the CINeMa approach, the confidence rating of this NMA ranged from “very low” to “low” for various comparisons. Conclusion: Based on the NMA, ATK + C, SY + C, KAP + C and JL + C were associated with more preferable and options for CRC patients when referring to ORR, performance status, nausea and vomiting, and leukopenia, respectively. However, owing to the limitations of this research, the above conclusions require further verification by more high-quality RCTs. PROSPERO registration: CRD42020160658.
format	article
author	Mo Tang PhD Student Bin He Doctor Jiawei Zhai Master Lei Wang PhD Student
author_facet	Mo Tang PhD Student Bin He Doctor Jiawei Zhai Master Lei Wang PhD Student
author_sort	Mo Tang PhD Student
title	Oral Chinese Patent Medicine Combined With Oxaliplatin-Based Chemotherapy Regimen for the Treatment of Colorectal Cancer: A Network Meta-Analysis
title_short	Oral Chinese Patent Medicine Combined With Oxaliplatin-Based Chemotherapy Regimen for the Treatment of Colorectal Cancer: A Network Meta-Analysis
title_full	Oral Chinese Patent Medicine Combined With Oxaliplatin-Based Chemotherapy Regimen for the Treatment of Colorectal Cancer: A Network Meta-Analysis
title_fullStr	Oral Chinese Patent Medicine Combined With Oxaliplatin-Based Chemotherapy Regimen for the Treatment of Colorectal Cancer: A Network Meta-Analysis
title_full_unstemmed	Oral Chinese Patent Medicine Combined With Oxaliplatin-Based Chemotherapy Regimen for the Treatment of Colorectal Cancer: A Network Meta-Analysis
title_sort	oral chinese patent medicine combined with oxaliplatin-based chemotherapy regimen for the treatment of colorectal cancer: a network meta-analysis
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/04521a5b15b745b0b8b45078ebadc178
work_keys_str_mv	AT motangphdstudent oralchinesepatentmedicinecombinedwithoxaliplatinbasedchemotherapyregimenforthetreatmentofcolorectalcanceranetworkmetaanalysis AT binhedoctor oralchinesepatentmedicinecombinedwithoxaliplatinbasedchemotherapyregimenforthetreatmentofcolorectalcanceranetworkmetaanalysis AT jiaweizhaimaster oralchinesepatentmedicinecombinedwithoxaliplatinbasedchemotherapyregimenforthetreatmentofcolorectalcanceranetworkmetaanalysis AT leiwangphdstudent oralchinesepatentmedicinecombinedwithoxaliplatinbasedchemotherapyregimenforthetreatmentofcolorectalcanceranetworkmetaanalysis
_version_	1718403296938426368

Oral Chinese Patent Medicine Combined With Oxaliplatin-Based Chemotherapy Regimen for the Treatment of Colorectal Cancer: A Network Meta-Analysis

Ejemplares similares